NANOPARTICLE, PREPARATION PROCESS AND USES THEREOF

Abstract

The present disclosure provides a nanoparticle, a preparation process thereof, a method for enhancing effect of a liver cancer drug, and a method for ameliorating tumor hypoxia by using the nanoparticle.

Claims

1. A nanoparticle, comprising: a core comprising manganese dioxide, and at least one negatively charged lipid carrier, and an anti-angiogenesis drug, wherein the negatively charged lipid carrier encapsulates the manganese dioxide, and the core is encapsulated in a polymer and a lipid by a multiple phase emulsion reaction to form the nanoparticle, wherein the at least one negatively charged lipid carrier is 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), the anti-angiogenesis drug is hydrophobic, and the polymer is poly D,L-lactide-co-glycolic acid (PLGA).

2. The nanoparticle according to claim 1 has a particle diameter ranging from 20 nm to 500 nm.

3. (canceled)

4. (canceled)

5. The nanoparticle according to claim 1, wherein the anti-angiogenesis drug is Sorafenib.

6. (canceled)

7. The nanoparticle according to claim 1, wherein the lipid is an emulsifier or a stabilizer.

8. The nanoparticle according to claim 7, wherein the emulsifier is selected from the group consisting of D--Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl alcohol (PVA), and any combination thereof; and the stabilizer is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG Mal), cholesterol, 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and any combination thereof.

9. The nanoparticle according to claim 8, further comprising a target peptide, and the target peptide is a SP94 peptide.

10. The nanoparticle according to claim 1, wherein the core is a solid core.

11. The nanoparticle according to claim 1, which is applied in a contrast agent for magnetic resonance imaging.

12. A process to prepare a nanoparticle, comprising the steps of: (a) mixing a first microemulsion with a second microemulsion, and performing a reduction reaction to form a mixture, wherein the first microemulsion comprises ascorbic acid and sodium hydroxide, and the second microemulsion comprises at least one negatively charged lipid carrier and potassium permanganate; (b) subjecting the mixture to a first centrifugation to remove a supernatant and obtaining a core; and (c) encapsulating the core in a polymer and a lipid by a multiple phase emulsion reaction to form the nanoparticle; wherein the core comprises manganese dioxide and the negatively charged lipid carrier, and the negatively charged lipid carrier encapsulates the manganese dioxide.

13. The process according to claim 12, further comprising the step of mixing the nanoparticle with an anti-angiogenesis drug, so that the nanoparticle comprises the anti-angiogenesis drug, wherein the anti-angiogenesis drug is hydrophobic.

14. The process according to claim 13, wherein the polymer is poly D,L-lactide-co-glycolic acid (PLGA).

15. The process according to claim 14, wherein the lipid is an emulsifier or a stabilizer, and the nanoparticle is further subjected to a second centrifugation after the multiple phase emulsion reaction.

16. The process according to claim 15, further comprising the step of conjugating the nanoparticle with a target peptide, wherein the target peptide is a SP94 peptide.

17. A method for enhancing effect of a liver cancer drug, comprising administering to a subject in need thereof an agonist comprising an effective amount of the nanoparticle according to claim 1.

18. A method for ameliorating tumor hypoxia, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of the nanoparticle according to claim 1.

19. The method according to claim 18, wherein the tumor hypoxia is liver tumor hypoxia.

20. The method according to claim 19, wherein the nanoparticle reverses epithelial-mesenchymal transition (EMT) induced by the liver tumor hypoxia.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The following drawings form part of the present specification and are included here to further demonstrate some aspects of the present invention, which can be better understood by reference to one or more of these drawings, in combination with the detailed description of the embodiments presented herein.

[0032] FIG. 1A is a process flow diagram showing the preparation of the nanoparticles of the present invention.

[0033] FIG. 1B is a photograph showing the appearance of the nanoparticles of the present invention.

[0034] FIG. 1C is a schematic diagram showing the analysis of core components of the nanoparticles of the present invention using X-ray photoelectron spectroscopy (XPS).

[0035] FIG. 1D is another schematic diagram showing the analysis of core components of the nanoparticles of the present invention using X-ray photoelectron spectroscopy.

[0036] FIG. 2A is a schematic diagram showing the effect of the amount of PVA in water phase on the size of the nanoparticles, wherein ** indicates p<0.01; *** indicates p<0.001.

[0037] FIG. 2B is a schematic diagram showing the effect of the amount of TPGS in oil phase on the size of the nanoparticles, wherein * indicates p<0.05; ** indicates p<0.01.

[0038] FIG. 2C is a schematic diagram showing the effect of the content of TPGS on the encapsulation efficiency of Sorafenib in the PLGA-based NPs containing Sorafenib (Psor), wherein *** indicates p<0.001.

[0039] FIG. 2D is a schematic diagram showing the effect of different ratios of Sorafenib and manganese dioxide on the size of the nanoparticles, wherein ** indicates p<0.01.

[0040] FIG. 2E is a schematic diagram showing the effect of different ratios of Sorafenib and manganese dioxide on zeta-potential.

[0041] FIG. 2F is a schematic diagram showing the effect of different ratios of Sorafenib and manganese dioxide on the encapsulation efficiency of Sorafenib, wherein * indicates p<0.05.

[0042] FIG. 2G is an image drawing showing the appearance and size distribution of the nanoparticles of the present invention using transmission electron microscopy (TEM).

[0043] FIG. 3A is a schematic diagram showing the quenching of H.sub.2O.sub.2 by the nanoparticles of the present invention with pH-dependent reactivity, wherein the concentration of H.sub.2O.sub.2 is 300 M, and the concentration of manganese dioxide is 750 M; wherein *** indicates p<0.001.

[0044] FIG. 3B is a schematic diagram showing the drug release behaviors of the nanoparticles of the present invention, wherein ** indicates p<0.01, and *** indicates p<0.001.

[0045] FIG. 4A is a dyed drawing showing in vitro cellular uptake of the nanoparticles of the present invention, wherein the green represents Coumarin 6 (C6);

[0046] the blue represents the 4,6-diamidino-2-phenylindole (DAPI)-stained nuclei.

[0047] FIG. 4B is a schematic diagram showing in vitro cellular uptake of the nanoparticles of the present invention, wherein *** indicates p<0.001.

[0048] FIG. 4C is a dyed drawing showing the hypoxia reduction ability of the nanoparticles of the present invention in tumor cells.

[0049] FIG. 4D is a schematic diagram showing the hypoxia reduction ability of the nanoparticles of the present invention in tumor cells, wherein *** indicates p<0.001.

[0050] FIG. 4E is a schematic diagram showing the effect of the nanoparticles of the present invention on the proliferation of murine liver cancer cell HCA-1, wherein *** indicates p<0.001.

[0051] FIG. 4F is a schematic diagram showing the effect of the nanoparticles of the present invention on the proliferation of human liver cancer cell JHH-7, wherein *** indicates p<0.001.

[0052] FIG. 4G is a schematic diagram showing the effect of the nanoparticles of the present invention on the viability of murine liver cancer cell HCA-1, wherein * indicates p<0.05; *** indicates p<0.001.

[0053] FIG. 4H is a schematic diagram showing the effect of the nanoparticles of the present invention on the viability of human liver cancer cell JHH-7, wherein ** indicates p<0.01.

[0054] FIG. 5A is a schematic diagram showing the effect of the nanoparticles of the present invention on the mRNA levels of EMT regulators, epithelial markers, and mesenchymal markers, wherein * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001.

[0055] FIG. 5B is a schematic diagram showing the effect of the nanoparticles of the present invention on reducing the invasiveness of HCA-1 cells under hypoxia, wherein * indicates p<0.05; ** indicates p<0.01.

[0056] FIG. 5C is a cell staining drawing showing the effect of the nanoparticles of the present invention on reducing the invasiveness of HCA-1 cells under hypoxia.

[0057] FIG. 6A is an in vitro MR imaging and schematic diagram of the nanoparticles of the present invention.

[0058] FIG. 6B is an in vivo MR imaging diagram of the nanoparticles of the present invention.

[0059] FIG. 6C is an in vivo MRI schematic diagram of the nanoparticles of the present invention, wherein n.s. indicates no significant difference; ** indicates p<0.01; *** indicates p<0.001.

[0060] FIG. 7A is a fluorescent staining diagram of the effect of the nanoparticles of the present invention on ameliorating tumor hypoxia and angiogenesis, wherein the blue represents DAPI; the red represents CD31; the green represents anti-pimonidazole antibody; scale bar=50 m.

[0061] FIG. 7B is a schematic diagram showing the effect of the nanoparticles of the present invention on ameliorating tumor hypoxia, wherein ** indicates p<0.01.

[0062] FIG. 7C is a schematic diagram showing the effect of the nanoparticles of the present invention on reducing angiogenesis, wherein * indicates p<0.05; *** indicates p<0.001.

[0063] FIG. 8A is a schematic diagram showing the effect of the nanoparticles of the present invention on the growth of HCC, wherein * indicates p<0.05; *** indicates p<0.001.

[0064] FIG. 8B is a schematic diagram showing the effect of the nanoparticles of the present invention on orthotopic tumor metastasis, wherein * indicates p<0.05; *** indicates p<0.001.

[0065] FIG. 8C is a dyed drawing showing the effect of the nanoparticles of the present invention on orthotopic tumor metastasis.

[0066] FIG. 8D is a schematic diagram showing the effect of the nanoparticles of the present invention on the infiltration of TAMs into tumors, wherein * indicates p<0.05; ** indicates p<0.01.

[0067] FIG. 8E is a schematic diagram showing the effect of the nanoparticles of the present invention on the infiltration of CD8.sup.+ T cells into tumors, wherein * indicates p<0.05; ** indicates p<0.01.

[0068] FIG. 8F is a schematic diagram showing whole cell vaccine therapy for combining the nanoparticles of the present invention with tumor vaccine, wherein ** indicates p<0.01; *** indicates p<0.001.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0069] In the following detailed description of the embodiments of the present invention, reference is made to the accompanying drawings, which are shown to illustrate the specific embodiments in which the present disclosure may be practiced. These embodiments are provided to enable those skilled in the art to practice the present disclosure. It is understood that other embodiments may be used and that changes can be made to the embodiments without departing from the scope of the present invention. The following description is therefore not to be considered as limiting the scope of the present invention.

Definition

[0070] As used herein, the data provided represent experimental values that can vary within a range of 20%, preferably within 10%, and most preferably within 5%.

[0071] As used herein, the term nanoparticle refers to a particle having a particle diameter less than 1 m. Preferably, the nanoparticle of the present invention has a particle diameter between 20 nm and 500 nm.

[0072] As used herein, the term agonist refers to a molecule that directly, indirectly or substantially induces, promotes or enhances the biological activity or receptor activation of another molecule.

[0073] As used herein, the term tumor hypoxia refers to a physiological difference between the normal and the tumor tissue at the oxygen level, wherein the partial pressure of oxygen in the tumor tissue is reduced compared with that of the normal tissue.

[0074] As used herein, the term SP94 peptide refers to a hepatocellular carcinoma (HCC)-specific peptide ligand for the delivery of targeted drugs.

[0075] According to the present invention, the pharmaceutical composition can be made into a dosage form suitable for parenteral or oral administration using techniques well known to those skilled in the art, including, but not limited to, injection (e.g., sterile aqueous solution or dispersion), sterile powder, tablet, troche, pill, capsule, and the like.

[0076] According to the present invention, the pharmaceutical composition can be administered by a parenteral route selected from the group consisting of: intraperitoneal injection, subcutaneous injection, intramuscular injection, intravenous injection, sublingual administration, and transdermal administration.

[0077] According to the present invention, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier widely used in pharmaceutically manufacturing techniques. For example, the pharmaceutically acceptable carrier can comprise one or more reagents selected from the group consisting of solvent, buffer, emulsifier, suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome, and the like. The selection and quantity of these reagents falls within the professional literacy and routine technology of those skilled in the art.

[0078] According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), aqueous solution containing alcohol, and combinations thereof.

[0079] According to the present invention, the statistical analysis used in the following examples is performed by Student's t-test and Mann-Whitney U-test, and the p-value less than 0.05 is considered to be statistically significant.

Example 1

Preparation and Characteristics of Nanoparticles of Present Invention

[0080] FIG. 1A is a process flow diagram showing the preparation of the nanoparticles of the present invention. First, ascorbic acid (Sigma Aldrich) was used to reduce potassium permanganate (KMnO.sub.4) (fisher scientific, Waltham, Mass.) to synthesize a core containing manganese dioxide, while a negatively charged lipid 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) (Avanti Polar Lipids, Alabaster) was used to coat the core. Briefly, two kinds of microemulsions (3 mL each), one contained DOPA lipid and KMnO4, another contained ascorbic acid, were prepared separately. To prepare the Mn.sup.7+-loaded microemulsions, 74 L of 35 mM DOPA and 40 L of 300 mM KMnO4 were dropped to the oil phase of cyclohexane and Igepal-520 (7:3, v/v). To prepare the ascorbic acid buffer-loaded microemulsions, 100 L of 250 mM ascorbic acid and 900 L of 1 M NaOH were mixed as ten times ascorbic acid buffer acting as reducing agent, and 40 L of ascorbic acid buffer were added into to the oil phase of cyclohexane and Igepal-520 (7:3, v/v). Two different kinds of microemulsions were mixed separately using a magnetic stir bar and plate for 10 minutes at room temperature. The emulsions were then mixed together and stirred for 40 minutes to form the condensed DOPA-coated MnO.sub.2 cores. Next, 6 mL of 100% ethanol (Sigma Aldrich, St. Louis, Mo.) was added to disrupt the emulsion, and the mixture was centrifuged at 20,133 g for 15 minutes. After removing the supernatant solution, the precipitated MnO.sub.2 cores were washed twice with 100% ethanol to remove the organic solvents with emulsifying agents, so that DOPA would surround the MnO.sub.2 cores by hydrophilicity and phosphate coordination (with manganese). After the removal of ethanol, the precipitate was then resuspended in 400 L of tetrahydrofuran (THF) (Sigma Aldrich, St. Louis, Mo.).

[0081] To formulate a drug-loadable nanoparticle, poly D,L-lactide-co-glycolic acid (PLGA) (50/50, inherent viscosity: 0.17 dl/g) (Green Square Materials Incorporation, Taoyuan, Taiwan) was used to carry Sorafenib and the core. D--Tocopherol polyethylene glycol 1000 succinate (TPGS) (Sigma Aldrich, St. Louis, Mo.) and other free lipids including 1,2-Dioleoyl-sn-glycero-3-phophocholine (DOPC), cholesterol, DSPE-PEG (2000) and DSPE-PEG Mal (Avanti Polar Lipids, Alabaster, Ala.) were used to stabilize the structure of the nanoparticles. That is, the MnO.sub.2 cores were subjected to a multiple phase emulsion reaction. Briefly, an organic phase mixture of 11.49 L of free lipids (molar ratio=DOPC: DSPE-PEG2000: DSPE-PEG2000 Mal: cholesterol=10:4:1:2), 5 L of 150 mg/mL PLGA, and 2.5 L of 132 mM TPGS dissolved in THF was mixed with 50 L of MnO2 cores (molar ratio of total free lipids to DOPA=1:2) and then the whole organic phase was added dropwise into water phase contained 0.25% (w/v) PVA (volume ratio of organic phase: water phase=1:8) under stirring with magnetic stir bar and plate for 10 minutes at room temperature. After oil in water emulsification, the nanoparticles were formed by the self-assembly and the solution was sonicated for 3 minutes using Q125 sonicator (Qsonica, Newtown, Conn.) following by 2 h gentle stirring.

[0082] To deliver Sorafenib and manganese dioxide to liver cancer cells, the SP94 peptide targeting liver cancer cells (SFSIIHTPILPL with the amino acid sequence of SEQ ID No: 1) synthesized and purified (96% purity) by Kelowna International Scientific Inc. (Taipei, Taiwan) was conjugated with DSPE-PEG Mal on the surface of the nanoparticles. Briefly, the SP94 peptide was reduced using immobilized TCEP disulfide-reducing gel (Thermo Fisher Scientific, USA) according to the manufacturer's suggestion. SP94 peptides were then added into nanoparticles solution where they would react with DSPE-PEG Mal on the surface of the nanoparticles. Thereafter, the solution was centrifuged at 25,001 g for 30 minutes at room temperature, and the nanoparticles were then resuspended in water to obtain nanoparticles containing SP94 peptides and MnO.sub.2 cores (i.e., SP94 PMD NPs) for further characterization, experiment or treatment. To synthesize nanoparticles containing SP94 peptides, Sorafenib and MnO.sub.2 cores (i.e., SP94 PMDsor NPs), same procedure was used and 37.5 L of 3.14 mM Sorafenib dissolved in THF was added in the organic phase.

[0083] FIG. 1B is a photograph showing the appearance of the nanoparticles of the present invention. As shown in FIG. 1B, only the negatively charged lipid DOPA can successfully prevent the cores from aggregation during synthesis of nanoparticles other than the positively charged lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or the neutral lipid 1,2-Dioleoyl-sn-glycero-3-phophocholine (DOPC). Therefore, the MnO.sub.2 cores can be stabilized by the DOPA lipid and maintain good dispersity for long time.

[0084] The characteristic analysis of the nanoparticles (NPs) of the present invention, the particle size and surface charge were measured using a Zetasizer (3000HS, Malvern Instruments Ltd., Worcestershire, UK) at room temperature. The X-ray photoelectron spectroscopy (XPS) samples were prepared by adding the cores of the present invention onto amino silane-coated silica chip and then analyzed by National Nano Device Laboratories (Hsinchu, Taiwan). The size and geometries of the NPs were analyzed by transmission electron microscopy (TEM; JEM2010, JEOL, Tokyo, Japan). The NPs were dried on formvar-coated 100-mesh copper grids in a vacuum chamber at room temperature for two days prior to imaging. The drug encapsulation efficiency of the nanoparticles containing Sorafenib and MnO.sub.2 cores (i.e., PMDsor NPs) was analyzed using a UV spectrophotometer (Multiskan, Thermo, USA) at 270 nm after the centrifugation. The absorbance of the supernatant of PMDsor NPs was subtracted with the absorbance of the supernatant of the nanoparticles containing no Sorafenib (i.e., PMD NPs) to get the percentage of unencapsulated Sorafenib. Finally, the encapsulation efficiency can be calculated using the regression line of different concentrations of Sorafenib.

[0085] FIG. 1C and FIG. 1D are schematic diagrams showing the analysis of core components of the nanoparticles of the present invention using X-ray photoelectron spectroscopy (XPS). As shown in FIG. 1C and FIG. 1D, the component of the cores was MnO.sub.2 since the XPS peaks assigned to Mn (2p.sub.1/2) and Mn (2p.sub.3/2) at the binding energy (B.E.) of 653.78 and 641.98 eV respectively and peaks assigned to Mn (3 s) at the binding energy (B.E.) of 88.98 and 84.18 eV. These detected XPS peaks of the cores are consistent with the ones of MnO.sub.2, and thus proving the cores were made up of MnO.sub.2.

[0086] In the step of oil in water emulsification, the strategy using a co-surfactant, D--tocopherol polyethylene glycol 1000 succinate (TPGS) in oil phase and polyvinyl alcohol (PVA) (Sigma Aldrich, St. Louis, Mo.) in water phase was utilized to control the sizes of PLGA-based NPs. By this way, smaller droplets of microemulsions could be formed due to the reduction of surface tension and their sizes might further affect the drug release. Herein, the effects of the amount of emulsifiers, TPGS and PVA, on the size of PLGA-based NPs were investigated. FIG. 2A is a schematic diagram showing the effect of the amount of PVA in water phase on the size of the nanoparticles. As shown in FIG. 2A, there was a decrease in particle size, from 255 nm to 165 nm, when the concentration of PVA in water phase was increased from 0% to 0.25% (w/v) while the concentration of TPGS in oil phase fixed to 0.94% (w/v). FIG. 2B is a schematic diagram showing the effect of the amount of TPGS in oil phase on the size of the nanoparticles. As shown in FIG. 2B, there was either a decrease in particle size, from 190 to 165 nm, when the concentration of TPGS in oil phase was increased from 0.35% to 0.94% (w/v) while the concentration of PVA in water phase fixed to 0.25% (w/v).

[0087] FIG. 2C is a schematic diagram showing the effect of the content of TPGS on the encapsulation efficiency of Sorafenib in the PLGA-based NPs containing Sorafenib (Psor). As shown in FIG. 2C, there was significant decline in Sorafenib encapsulation efficiency with increasing concentration of TPGS from 0.35% to 0.94% (w/v).

[0088] In order to achieve the efficient co-delivery of Sorafenib as well as MnO.sub.2 cores, the effects of different ratios of Sorafenib and manganese dioxide on the size of the nanoparticles, zeta-potential and encapsulation efficiency of Sorafenib were explored, and the results are shown in FIGS. 2D to 2F. As shown in FIG. 2D and FIG. 2F, an increase in the amount of MnO.sub.2 cores neither competed the space for drug encapsulation inside PMDsor NPs nor enlarged nanoparticle size. The NPs even became smaller and the encapsulation efficiency went higher when more MnO.sub.2 cores were added into oil phase (molar ratio of MnO.sub.2 to Sorafenib, from 0 to 9.26) with fixed amount of Sorafenib. As shown in FIG. 2E, the zeta-potential of the NPs was not affected by an increased MnO.sub.2 cores (around 30 mV), inferring that the negatively charged DOPA was more likely staying inside with MnO.sub.2 rather than coming out to the surface of the PMDsor NPs. To optimize PMDsor NPs with the desired size and encapsulation efficiency, a molar ratio of 9.26 (MnO.sub.2/Sorafenib), a concentration of 0.25% PVA and 0.47% TPGS were selected for the synthetic process.

[0089] Table 1 shows the physical properties (including size, polydispersity indexes (PDIs) and zeta-potentials) and encapsulation efficiency of the nanoparticles of the present invention. As shown in Table 1, the average diameters of finalized formulation of PMDsor NPs were 136.210.95 nm, with polydispersity indexes (PDIs) of 0.1720.025, and the percentage of encapsulated Sorafenib was about 80%.

TABLE-US-00001 TABLE 1 Size Zeta-potential Encapsulation (nm) PDI (mV) Efficiency (%) 136.21 0.95 0.172 0.025 31.13 0.40 80.30 0.52

[0090] In addition, the morphology and size distribution of PMDsor NPs were observed by transmission electron microscopy (TEM), and the result is shown in FIG. 2G. As shown in FIG. 2G, PMDsor NPs were well-distributed spheres and the particle sizes are approximately 100 nm.

Example 2

pH-Dependent Reactivity, Drug Release Profiles and Oxygen Generation Effect of Nanoparticles of Present Invention

[0091] Oxidative stress caused by tumor growth can significantly increase the concentration of H.sub.2O.sub.2 in the tumor microenvironment. In order to utilize the endogenous H.sub.2O.sub.2 produced by cancer cells and generate O.sub.2 in situ, the MnO.sub.2 cores must be delivered to the tumor region.

[0092] The reactivity of the PMD NPs toward H.sub.2O.sub.2 was then investigated by observing H.sub.2O.sub.2 quenching and O.sub.2 generation. Herein, a PeroXOquant assay kit (Pierce, USA) was used to study if PMD NPs would be able to quench H.sub.2O.sub.2 with pH-dependent reactivity. For the quenching experiment, PMD NPs (750 M) or vehicle NPs (without MnO.sub.2 cores) were placed in Na.sub.2HPO.sub.4NaH.sub.2PO.sub.4 buffer at pH 5.5 or 7.4, and H.sub.2O.sub.2 (300 M) was added to initiate the reaction. The residual amount of H.sub.2O.sub.2 was determined over time using the PeroXOquant assay kit. The result is shown in FIG. 3A.

[0093] FIG. 3A is a schematic diagram showing the quenching of H.sub.2O.sub.2 by the nanoparticles of the present invention with pH-dependent reactivity. As shown in FIG. 3A, 300 M of H.sub.2O.sub.2 could be completely quenched by 750 M of MnO.sub.2 in the solution at two different pH values (pH 5.5 and pH 7.4) after 24 hours. The PMD NPs thus have long-term quenching effect.

[0094] The cumulative release of Sorafenib from PMDsor NPs in the solutions at different pH values with or without 500 M H.sub.2O.sub.2 was continuously observed for several time points. The release profiles of Sorafenib from PMDsor NPs were investigated in PBS buffer (pH 7.4) and acetic acid buffer (pH 5.5) with or without H.sub.2O.sub.2 at 37 C. Briefly, Sorafenib-loaded NPs were put into centrifuge tubes and dispersed in 1 mL of buffer with or without H.sub.2O.sub.2 (500 M). The tubes were put in an orbital shaker incubator and vibrated at 150 rpm at 37 C. At the designed time points after incubation, PMDsor NPs were centrifuged at 25,001 g for 30 minutes at 25 C. The pellets were then dissolved in 100 L of dimethylsulfoxide (DMSO) and following by centrifugation at 25,001 g for 30 min at 25 C. again to remove the pellet. The supernatant with sorafenib was analyzed by a UV spectrophotometer at 270 nm. Finally, the drug release percentage can be calculated using the regression line of Sorafenib. The result is shown in FIG. 3B.

[0095] FIG. 3B is a schematic diagram showing the drug release behaviors of the nanoparticles of the present invention. As shown in FIG. 3B, compared with the solutions without adding H.sub.2O.sub.2, the release profiles of PMDsor NPs at pH 5.5 and pH 7.4 were both significantly promoted by the presence of H.sub.2O.sub.2. Moreover, the release of Sorafenib at pH 5.5 was also speeded up compared with pH 7.4, indicating that the nanoparticles of the present invention have better drug release efficiencies in the acidic environment, such as the tumor microenvironment.

Example 3

In Vitro Cellular Uptake and Efficacy of SP94-Conjugated NPs

[0096] The NPs modified with tumor targeting peptides SP94 are the suitable carrier for the MnO.sub.2 cores. The cellular uptake of targeted or non-targeted PMD NPs in HCA-1 murine liver cancer cells (provided by Dr. Dan Duda) and Hep3B human liver cancer cells (purchased from the American Type Culture Collection (ATCC)) was measured.

[0097] Coumarin 6 (C6), a hydrophobic small molecule, was used as a fluorescent tracer in the PLGA-based NPs, formulated with a final weight ratio of C6 to PLGA as 1/150. HCA-1 or Hep3B cells (110.sup.4 cells/mL) were seeded in the 12-well plates (Costar, Ill., USA) and incubated for 12 hours. The cells were then treated with C6-containing SP94 PMD (i.e., SP94 PLGA-based manganese dioxide (PMD)-C6 NPs) or C6-containing PMD NPs (i.e., PMD-C6 NPs), at 37 C. for 4 hours. After removing the medium in each well, the cells were washed with PBS and fixed with 4% paraformaldehyde for 10 minutes. After aspiration of paraformaldehyde, cells were washed with PBS and counterstained with DAPI (Vector Laboratories, Burlingame, Calif.). The HCA-1 and Hep3B uptake of C6 was examined and quantified using a confocal microscope (LSM-780, Carl Zeiss, Germany). The results are shown in FIG. 4A and FIG. 4B.

[0098] FIG. 4A is a dyed drawing showing in vitro cellular uptake of the nanoparticles of the present invention. FIG. 4B is a schematic diagram showing in vitro cellular uptake of the nanoparticles of the present invention. As shown in FIG. 4A and FIG. 4B, all the NPs containing PLGA and MnO.sub.2 cores (i.e., PMD NPs) were labeled with coumarin 6 (C6), a fluorescent molecule, and the cellular uptake of C6 was greater as being formulated in SP94 PMD-C6 NPs than PMD-C6 NPs after 4 h incubation.

[0099] Next, a Hypoxyprobe was used to test the hypoxia reduction ability of SP94 PMD NPs. The HCA-1 cells (5000 cells/well) were seeded on the coverslips in two 24-well plates (Costar, Ill.) one day before treatment. After treated with different concentrations of SP94 PMD NPs (0, 20, 80 M), the PMD-treated plates were cultured under hypoxic condition (1% O.sub.2) for 24 hours. The untreated plates were incubated under normoxic condition for 24 hours as control group. Then the plates were changed to serum free medium containing 0.5 M pimonidazole hydrochloride (Hypoxyprobe, Burlington, Mass.) and put back into the incubators with previous conditions for 4 hours. The cells were washed with 0.5 mL PBS, then fixed with 4% paraformaldehyde at room temperature for 10 minutes. Washed twice with PBS to remove paraformaldehyde (Sigma Aldrich, St. Louis, Mo.), the cells were permeabilized with PBS containing 0.5% Triton X-100 at room temperature for 30 minutes. Washed three times with PBS, the coverslips were blocked with 5% BSA in PBS at room temperature for 1 hour. The cells were treated with anti-pimonidazole antibody (HP-FITC-Mab, 1:100 in 1% BSA/PBS) (Hypoxyprobe, Burlington, Mass.) and kept in dark at room temperature for 2 hours. Washed the coverslips five times with PBS, the nuclei were stained with DAPI (Vector Laboratories, Burlingame, Calif.). The immunocytochemistry was observed and quantified using a confocal microscope (LSM-780, Carl Zeiss, Germany) The results are shown in FIG. 4C and FIG. 4D.

[0100] FIG. 4C is a dyed drawing showing the hypoxia reduction ability of the nanoparticles of the present invention in tumor cells. FIG. 4D is a schematic diagram showing the hypoxia reduction ability of the nanoparticles of the present invention in tumor cells. As shown in FIG. 4C and FIG. 4D, as the cells were treated with SP94 PMD NPs, the hypoxic condition detected by anti-pimonidazole antibodies was significantly decreased (2-fold decrease of fluorescence). The result indicated the successful production of O.sub.2 by incubating SP94 PMD NPs with liver cancer cells under hypoxic stress.

[0101] To investigate the ability of SP94 PMDsor NPs in sensitizing HCC to Sorafenib and inhibiting cancer cells proliferation, murine liver cancer cell HCA-1 and human liver cancer cell JHH-7 (provided by Dr. Dan Duda) were treated with SP94 PMDsor NPs either under normoxia or hypoxia. The in vitro cell proliferation of the treatment using different nanoparticles (PLGA vehicles, SP94 PMD, PLGA vehicles containing Sorafenib (SP94 Psor), SP94 PMDsor) was simply examined by cell counting. According to a modified protocol, both JHH-7 and HCA-1 cells (10.sup.4 cells per well) were seeded in two 12-well plates (Costar, Ill.), incubated for 12 hours and the plates would be either moved into the hypoxia incubator (1% O.sub.2) or normoxia incubator. After 8 hours, cells would be trypsinized for counting (cell numbers of Day 0) or exposed to different nanoparticles. The number of cells would be counted for continuous 3 days (cell numbers of Day 1, 2, and 3), after the treatment of different nanoparticles in both hypoxia and normoxia. The results are shown in FIG. 4E and FIG. 4F.

[0102] FIG. 4E is a schematic diagram showing the effect of the nanoparticles of the present invention on the proliferation of murine liver cancer cell HCA-1. FIG. 4F is a schematic diagram showing the effect of the nanoparticles of the present invention on the proliferation of human liver cancer cell JHH-7. As shown in FIG. 4E and FIG. 4F, Sorafenib-contained NPs (SP94 Psor) loses its ability to suppress cancer cell growth in both cell lines under hypoxia. However, SP94 PMDsor NPs simultaneously delivering MnO.sub.2 cores and Sorafenib could significantly sensitize both JHH-7 and HCA-1 cells to Sorafenib under hypoxia. The result shows that the nanoparticles of the present invention can efficiently generate oxygen to ameliorate hypoxia-induced Sorafenib resistance of cancer cells and reduce the growth rates of cancer cells.

[0103] The in vitro cell viability of different formulations of NPs was examined using the MTT assay. HCA-1 and JHH-7 cells (1000 cells per well) were seeded in 96-well plates (Costar, Ill.), incubated for 12 hours and treated with different formulations (PLGA vehicles, SP94 PMD, SP94 Psor, SP94 PMDsor) in serum free medium. After 72 hours, 15 L of 5 mg/mL MTT dissolved in PBS was added to each well and incubated for 3 hours at 37 C. The medium was aspirated, and 50 L of DMSO was added to each well. The absorbance was measured using a UV spectrophotometer (Multiskan, Thermo, USA) at 570 nm. The results are shown in FIG. 4G and FIG. 4H.

[0104] FIG. 4G is a schematic diagram showing the effect of the nanoparticles of the present invention on the viability of murine liver cancer cell HCA-1. FIG. 4H is a schematic diagram showing the effect of the nanoparticles of the present invention on the viability of human liver cancer cell JHH-7. As shown in FIG. 4G and FIG. 4H, in both relative Sorafenib-resistant cell line HCA-1 and Sorafenib-sensitive cell line JHH-7, SP94 PMDsor NPs could significantly sensitize the drug to cells under hypoxic condition compared with SP94 Psor NPs. The result demonstrated a synergistic effect is exerted when Sorafenib is co-delivered with the nanoparticles of the present invention. Hence, the nanoparticles of the present invention can not only effectively generate oxygen to alleviate tumor hypoxia, but also act as an agonist for enhancing effect of liver cancer drugs.

Example 4

Evaluation of Effect of Nanoparticles of Present Invention on Reversing Epithelial-Mesenchymal Transition (EMT) and Reducing Invasiveness of Liver Cancer Cells

[0105] The epithelial-mesenchymal transition (EMT) has been recognized as an essential process to raise the invasiveness of tumor during the cancer progression of hepatocellular carcinoma (HCC). To examine whether SP94 PMD NPs could suppress the induction of EMT by hypoxia, quantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify mRNA levels of EMT regulators (including Slug, Snail, Zeb2, and Twist1), epithelial markers (including E-cadherin and MTA3), and mesenchymal markers (including vimentin, fibronectin and N-cadherin), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as an internal reference gene. HCA-1 (110.sup.6 cells) were seeded in two 12-well plates. After incubated for 12 hours, one plate would be moved into hypoxia incubator (1% O.sub.2) and another plate would be kept in normoxia incubator as control group. After 8 hours, the cells in hypoxic condition were treated with different concentrations of SP94 PMD NPs (0, 20, 40 M) and then incubated under hypoxia again for 48 hours. Total RNA was prepared with TRIzol reagent (Life Technologies, USA), and complementary DNA (cDNA) was reverse-transcribed with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). PCR primer sequences are shown in the following Table 2. The cDNA from cells was amplified with specific primers with a PowerUp SYBR Green Master Mix (Applied Biosystems, USA) and a 7500 Real Time PCR System (Applied Biosystems, USA). The expression of mRNA of the target gene was evaluated by the comparative C.sub.T method.

TABLE-US-00002 TABLE2 Genes Forwardprimers Reverseprimers Cdh2 5-AGCGCAGTCTTACCGAAGG-3 5-TCGCTGCTTTCATACTGAACTTT-3 (SEQIDNo:2) (SEQIDNo:3) Fn1 5-TGTGACCAGCAACACGGTG-3 5-ACAACAGGAGAGTAGGGCGC-3 (SEQIDNo:4) (SEQIDNo:5) Vim 5-CTTGAACGGAAAGTGGAATCCT-3 5-GTCAGGCTTGGAAACGTCC-3 (SEQIDNo:6) (SEQIDNo:7) Cdh1 5-CAGTCATAGGGAGCTGTCTA 5-GGGTACACGCTGGGAAACAT-3 CCAAA-3(SEQIDNo:8) (SEQIDNo:9) Mta3 5-AAAAGCAGAAGCACCAGGAA-3 5-GGCCCATCTAGACCATTGTG-3 (SEQIDNo:10) (SEQIDNo:11) Snai1 5-CACACGCTGCCTTGTGTCT-3 5-GGTCAGCAAAAGCACGGTT-3 (SEQIDNo:12) (SEQIDNo:13) Snai2 5-TGGTCAAGAAACATTTCAACGCC-3 5-GGTGAGGATCTCTGGTTTTGGTA-3 (SEQIDNo:14) (SEQIDNo:15) Zeb2 5-ATTGCACATCAGACTTTGAGGAA-3 5-ATAATGGCCGTGTCGCTTCG-3 (SEQIDNo:16) (SEQIDNo:17) Twist1 5-CTGCCCTCGGACAAGCTGAG-3 5-CTAGTGGGACGCGGACATGG-3 (SEQIDNo:18) (SEQIDNo:19)

[0106] FIG. 5A is a schematic diagram showing the effect of the nanoparticles of the present invention on the mRNA levels of EMT regulators, epithelial markers, and mesenchymal markers. As shown in FIG. 5A, expression of Slug, Snail, Zeb2, Twist1, Vimentin, Fibronectin, and N-cadherin significantly increased when HCA-1 cells were cultured in hypoxic condition. After the treatment of SP94 PMD NPs with two different concentrations (20 and 40 M), the changes of these genes were reversed back and closer to normoxic level, indicating the inhibition of EMT. On the other hand, the mRNA levels of E-cadherin and MTA3 increased significantly with the treatment of 40 M SP94 PMD NPs while HCA-1 cells were kept under hypoxia. These data indicated that induction of EMT in HCA-1 by hypoxia could be reversed by SP94 PMD NPs.

[0107] The invasiveness of cancer cells is related to metastasis, a main cause of death in cancer patients. To evaluate whether SP94 PMD NPs could reduce the invasiveness of HCA-1 under hypoxia, the transwell inserts from Millipore were used. HCA-1 cells were trypsinized and pelleted by centrifugation. Removed supernatant, then the cells were resuspended in serum free medium to prepare the suspension (510.sup.5 cells/mL). The cell suspension was added to the top of the filter membrane in a transwell insert (Millipore Corp., Billerica, Mass.). The upper chambers were added with different concentrations of SP94 PMD NPs (0, 20, 40 M). Culture medium supplemented with 10% FBS was carefully added to the lower chamber in a 24-well plate (Costar, Ill.). The cells were incubated for 72 hours at 37 C. under the condition of hypoxia (1% O.sub.2) and 5% O.sub.2. The medium was removed, and the upper face of the membrane was washed with PBS twice and the remaining cells were carefully removed by cotton. The lower face of the membrane was then fixed with 4% paraformaldehyde at room temperature for 5 minutes. The paraformaldehyde was removed from the plates and the invaded cells were stained with 1% crystal violet (Sigma Aldrich, St. Louis, Mo.) in 90% ethanol for 30 minutes. The stained membrane was repeatedly soaked in fresh PBS to remove the crystal violet. The membrane was observed with the cell-migrated side up using an inverted microscope (IX83, OLYMPUS, Japan) and the number of cells in different fields were counted using Image J. The results are shown in FIG. 5B and FIG. 5C.

[0108] FIG. 5B is a schematic diagram showing the effect of the nanoparticles of the present invention on reducing the invasiveness of HCA-1 cells under hypoxia. FIG. 5C is a cell staining drawing showing the effect of the nanoparticles of the present invention on reducing the invasiveness of HCA-1 cells under hypoxia. As shown in FIG. 5B and FIG. 5C, the number of invaded cells was quantified by directly counting in the pictures and there was at least 3-fold decrease in SP94 PMD NPs-treated cells invading toward the lower chamber compared with untreated cells within the 1% O.sub.2 atmosphere. The results indicated that the hypoxic stress would enhance the invasiveness of HCA-1 cells and treatment with SP94 PMD NPs could significantly reduce the numbers of invaded cells.

Example 5

In Vitro and In Vivo MR Imaging of SP94 PMD NPs

[0109] It is known that MnO.sub.2 nanoparticles were generally insoluble and remained stable at neutral pH. However, after being internalized by cells the particles could be degraded in the acidic organelle (endosome or lysosome) releasing Mn.sup.2+ ions which are known to be potent T1 MRI contrast agents. For in vitro MRI, PMD NPs solution with different concentrations was prepared in pH 5.5 and pH 7.4 buffer added with 1 mM H.sub.2O.sub.2. The solutions were scanned under a 7T animal MRI scanner (Bruker, USA). The relaxation rates r1 (1/T1) under different pH values were calculated from T1 values at different Mn concentrations. The result is shown in FIG. 6A.

[0110] FIG. 6A is an in vitro MR imaging and schematic diagram of the nanoparticles of the present invention. As shown in FIG. 6A, T1 images of PMD NPs exhibited significant brightening effect in a concentration-dependent manner at pH 5.5, whereas the contrast effect in neutral condition was not detected. Furthermore, the relaxation rates r1 (1/T1) at pH 5.5 (3.505 mM.sup.1 s.sup.1) was significant higher than r1 in neutral condition (0.138 mM.sup.1 s.sup.1), indicating the successful production of Mn.sup.2+ ions.

[0111] For in vivo MRI, male C3H/HeNCrNarl (4-5 weeks old, 25 g) mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan). HCA-1 cells were implanted heterotopically in the right legs via subcutaneous injection. The mice were conducted after 4 weeks of tumor growth. Animal care and use were performed in compliance with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources, National Research Council, published by the National Academy Press. Animals were scanned by a 7T animal MRI scanner (Bruker, USA) before and after i.v. injection of SP94 PMD NPs at a dose of 20 mg/kg of MnO.sub.2. The results are shown in FIG. 6B and FIG. 6C.

[0112] FIG. 6B is an in vivo MR imaging diagram of the nanoparticles of the present invention. FIG. 6C is an in vivo MRI schematic diagram of the nanoparticles of the present invention. As shown in FIG. 6B and FIG. 6C, the contrast enhancement caused by SP94 PMD NPs was observed at 5 minutes post injection. At 1 hour post injection of SP94 PMD NPs, the T1 signals of tumor enhanced 1.45 fold while the T1 signals of muscle showed no significant difference indicating successful delivery and decomposition of the MnO.sub.2 cores in the tumor microenvironment. The result indicated that the nanoparticles of the present invention can be used as an MRI contrast agent, particularly in the tumor microenvironment.

Example 6

In Vivo Efficacy of Targeted SP94 PMDsor NPs

[0113] It is known that tumor microenvironment has the characteristics favoring the reaction between MnO.sub.2 and H.sub.2O.sub.2 with the acidic pH and elevated levels of H.sub.2O.sub.2. Hence, the NPs containing MnO.sub.2 might be able to generate oxygen and relieve tumor hypoxia by reacting with endogenous H.sub.2O.sub.2 produced by cancer cells. Sorafenib acting as an anti-angiogenesis drug can reduce blood vessels formation and reduce the supply of oxygen and nutrient in HCC. However, the anti-angiogenesis effect can lead to severe tumor hypoxia. Herein, both tumor hypoxia and blood vessels in different treatment groups by Hypoxyprobe and CD31 were investigated respectively. To establish orthotopic model for treatment, five-week-old male mice were implanted with HCA-1 cells (210.sup.6 cells) in a 20 L Matrigel solution in their livers. The HCA-1 tumor bearing mice were treated ten days after implantation. HCA-1 tumor-bearing mice were treated with different formulations (SP94 PMD, SP94 Psor, and SP94 PMDsor NPs) at a dose of 5 mg/kg of Sorafenib and 10 mg/kg of MnO.sub.2 by intravenous injection (three doses per week for 2 weeks). The therapeutic efficacy and the change of tumor microenvironments was analyzed after two weeks of treatment.

[0114] The tumor volume was calculated with the following formula: volume=widthlengthheight/2. HCA-1 tumor bearing mice were treated as the treatment plan. At 6 hours post injection of the last dose of different formulations, tumors were excised 60 minutes after i.v. injection with pimonidazole hydrochloride (60 mg/kg) (Hypoxyprobe, Burlington, Mass.) and fixed with 4% PFA (in PBS) overnight. After fixation, tumors were dehydrated with 30% sucrose (Sigma Aldrich, St. Louis, Mo.) and embedded in OCT compound (Sakura Finetek USA, Inc., Torrance, Calif.). Frozen section (10 m thick) for immunofluorescence staining were fixed in acetone at 20 C. for 10 minutes and washed with PBS. The sections were then blocked with 5% bovine serum albumin for 1 hour and incubated with anti-pimonidazole antibodies conjugated with FITC (1:100 in 1% BSA/PBS, Hypoxyprobe, Burlington, MA), and rabbit anti-CD31 mouse antibodies (1:100 in 1% BSA/PBS, abcam, England) at 4 C. After washed with PBS, the sections were further incubated with Alexa Fluor 647 secondary anti-rabbit IgG antibodies (1:200 in 1% BSA/PBS, Thermo Fisher Scientific, USA) for 1 hour. Unbound secondary antibodies were washed away with PBS. Cell nuclei were counterstained with DAPI (Vector Laboratories, Burlingame, Calif.). The images were observed using a confocal microscope (LSM780, Zeiss, Germany). The results are shown in FIG. 7A to FIG. 7C.

[0115] FIG. 7A is a fluorescent staining diagram of the effect of the nanoparticles of the present invention on ameliorating tumor hypoxia and angiogenesis. FIG. 7B is a schematic diagram showing the effect of the nanoparticles of the present invention on ameliorating tumor hypoxia. FIG. 7C is a schematic diagram showing the effect of the nanoparticles of the present invention on reducing angiogenesis. As shown in FIG. 7A and FIG. 7B, SP94 PMD and SP94 PMDsor NPs significantly reduced the green fluorescence compared with the control group, indicating the MnO.sub.2 NPs could successfully reduce tumor hypoxia by triggering the decomposition of H.sub.2O.sub.2 and generation of O.sub.2 in tumor. As shown in FIG. 7A to FIG. 7C, despite the significant reduction of blood vessels that were observed in tumor tissues after the treatment of SP94 Psor and SP94 PMDsor NPs, the hypoxic situation only became much more severe after administrating SP94 Psor NPs. In contrast, tumor hypoxia was attenuated to a lower level upon treatment with SP94 PMDsor NPs, indicating that adding MnO.sub.2 cores to the Sorafenib-contained NPs can suppress the increased tumor hypoxia caused by Sorafenib. In addition, as shown in FIG. 7A and FIG. 7C, a significant decrease in blood vessels signals was observed while only treated with SP94 PMD NPs without drug loading. Therefore, SP94 PMD NPs might be able to inhibit angiogenesis by solving tumor hypoxia. Incorporation of MnO.sub.2 cores to sorafenib-contained NPs suppressing the tumor hypoxia may result in enhanced anti-angiogenic therapy.

[0116] Next, the impact of HCC growth after treatment with SP94 PMDsor NPs was evaluated. The result is shown in FIG. 8A. FIG. 8A is a schematic diagram showing the effect of the nanoparticles of the present invention on the growth of HCC. As shown in FIG. 8A, co-delivery of Sorafenib and the MnO.sub.2 cores by SP94 PMDsor NPs significantly inhibited the primary HCA-1 tumor growth. In contrast, SP94 Psor NPs only induced moderate tumor growth suppression and SP94 PMD NPs showed no significant tumor growth inhibition. In the orthotopic HCA-1 tumor model, spontaneous lung metastases happen and form detectable nodules approximately 4 weeks after tumor implantation. Herein, the lung tissues were also collected to observe the metastasis modulation. The lung tissue was cut into small pieces and fixed in 4% PFA (in PBS) overnight before being embedded in paraffin wax. The sections were then stained with hematoxylin and eosin (H&E) and observed with an inverted microscope (IX83, OLYMPUS, Japan). The results are shown in FIG. 8B and FIG. 8C.

[0117] FIG. 8B is a schematic diagram showing the effect of the nanoparticles of the present invention on orthotopic tumor metastasis. FIG. 8C is a dyed drawing showing the effect of the nanoparticles of the present invention on orthotopic tumor metastasis. As shown in FIG. 8B and FIG. 8C, although SP94 Psor NPs moderately suppressed primary tumor growth, the occurrences of metastasis after the treatment of SP94 Psor NPs only slightly reduced compared with control group. However, amelioration of tumor hypoxia by delivery of the MnO.sub.2 cores using both SP94 PMD and SP94 PMDsor NPs significantly decreased the amount of lung metastatic nodules.

[0118] Treatment of Sorafenib significantly induced an increase in intratumoral infiltration of tumor-associated macrophages (TAMs) which help tumor progression and metastasis. Moreover, the improvement of tumor oxygenation can not only enhance the immune activity by promoting T-cell proliferation and survival inside the tumor but also strengthen tumor vascular function via vessel normalization which facilitating T-cell tumor infiltration. Thus, the effect of various formulations of Sorafenib treatment on TAMs and CD8.sup.+ T cells infiltration into tumors was evaluated by flow cytometry. Tumor-bearing mice were anesthetized first, perfused via intracardiac injection with PBS and then sacrificed. Tumor tissues were collected and harvested in enzyme-contained DMEM cell culture medium (1.5 mg/mL of collagenase type 1A and hyaluronidase). The tissues were cut and grinded into smaller pieces, and then digested for 1 hour at 37 C. to form the suspension of single tumor cell. The suspension was filtered through a 70-m cell strainer (Corning, Manassas, Va.) and the cells were washed 3 times following by resuspending in cold flow buffer (1% BSA, 0.1% NaN.sub.3 in PBS). Single-cell suspensions were incubated with the following monoclonal anti-mouse antibodies: F4/80-PE (eBiosciences, San Diego, Calif.), 7-AAD, CD3e-APC, CD8a-PE-Cy7, CD45-FITC and CD4-PE (BD Biosciences, East Rutherford, N.J.). Flow cytometry data were acquired on a BD FACSAria III flow cytometry and analyzed with FACSDiva software. The results are shown in FIG. 8D and FIG. 8E.

[0119] FIG. 8D is a schematic diagram showing the effect of the nanoparticles of the present invention on the infiltration of TAMs into tumors. FIG. 8E is a schematic diagram showing the effect of the nanoparticles of the present invention on the infiltration of CD8.sup.+ T cells into tumors. As shown in FIG. 8D and FIG. 8E, in HCA-1 tumors, the infiltration of F4/80.sup.+ TAMs significantly increased only in SP94 Psor-treated group, while the CD8.sup.+ T cells remained at a basal level. In contrast, the significant decrease in TAMs and increase in CD8.sup.+ T cells tumor infiltration were observed after treatment with SP94 PMD or SP94 PMDsor NPs, indicating that the TAMs infiltration might be suppressed and CD8.sup.+ T cells infiltration might be facilitated by reducing tumor hypoxia.

[0120] As the result, the tumor vaccine was further combined with SP94 PMDsor NPs in the treatment. The fragment of codon-optimized GM-CSF (cGM-CSF) was amplified by PCR using the cGM-CSF forward primer: 5-ACTC*GCTAGC*ATGGCCCACGAGAG-3 (SEQ ID No: 20) and reverse primer: 5-CGT*GAATTC*TCACTTCTGCACGGG-3 (SEQ ID No: 21) incorporated Nhel and EcoRI restrictions site in primer (underlined). p-cGM-CSF was constructed by digest restriction enzymes, ligated and cloned into the eukaryotic expression vector pcDNA3.1() (Invitrogen, Carlsbad, USA) plasmid. Strain DH5 was transformed with plasmids encoding cGM-CSF. Plasmids were next purified with PureLink HiPure Plasmid gigaprep kit (Thermo Fisher Scientific, USA). The plasmids were resuspended at 1 mg/ml in ddH2O and stored at 20 C. HCA-1 cells were seeded in 6 wells plate and attached overnight. The plasmids were mixed with lipofectamine 2000 (Thermo Fisher Scientific, USA) in the opti-mem medium. The mixture was added into the cells and incubated for 24 hours. The transfected cells were selected by G418 (300 g/mL). After the selection, the cGM-CSF-overexpressing HCA-1 cell line was obtained for vaccine production.

[0121] Whole liver cancer cell vaccine was generated from cGM-CSF-overexpressing HCA-1 cells. Cells were detached by EDTA and washed for three times. After washed, cells were resuspended in PBS (10.sup.7 cells/mL) and incubated with mitomycin C (50 g/mL) for 1 hour at 37 C. In the HCC tumor model, 3 days after tumor implantation, mice were injected i.p. five times (at 2- to 3-day intervals) with 510.sup.6 mitomycin C-treated cells. On the 10th day after tumor implantation, tumor-bearing C3H/HeNCrNar1 male mice were injected i.v. six times (three times per week) with SP94 PMDsor NPs (Sorafenib: 5 mg/kg, MnO.sub.2:10 mg/kg). Two weeks after the first NPs treatment, mice were sacrificed and tumor volume was measured. The result is shown in FIG. 8F.

[0122] FIG. 8F is a schematic diagram showing whole cell vaccine therapy for combining the nanoparticles of the present invention with tumor vaccine. As shown in FIG. 8F, although vaccine can moderately inhibited tumor growth, the combination with SP94 PMDsor NPs demonstrated better therapeutic efficacy. Therefore, the amelioration of tumor hypoxia by the NPs of the present invention can bring the benefits to tumor immunity and boost immunotherapy.

[0123] In summary, the nanoparticles of the present invention have the effect on good biocompatibility and stability, no damage to normal tissues, alleviation of tumor hypoxia, being used as an agonist for enhancing effect of a liver cancer drug, and as a contrast agent for cancer magnetic resonance imaging.

[0124] Although the present invention has been described with reference to the preferred embodiments, it will be apparent to those skilled in the art that a variety of modifications and changes in form and detail may be made without departing from the scope of the present invention defined by the appended claims.